secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001140361-23-025867
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO sells cystinosis gene therapy program to Novartis for $87.5M cash
-------------------------------------------------------------------------

- Sale of AVR-RD-04 to Novartis for $87.5M cash at closing; proceeds to extend cash runway into Q4 2024.
- AVROBIO retains full rights to Gaucher, Hunter, Pompe programs.
- Company expects to use ~$16.4M of proceeds to pay off Term Loan Facility with Silicon Valley Bank.
- Transaction expected to close by end of Q3 2023, subject to customary conditions.
- TD Cowen and Wells Fargo acted as financial advisors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123025867/0001140361-23-025867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123025867/ny20009215x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-025867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer